Speed generic drugs to market.

Marie Gluesenkamp Perez · Washington · Democratic

policy impact 0.57 specificity 0.77 extraction confidence 95%

Occurrences

And speeding generic drugs to market.

She commits to accelerating generic drug approval and market entry.

Washington’s 3rd Congressional District debate: Republican Joe Kent and Democrat Marie Gluesenkamp Perez - OPB
primary · debate · model gpt-5.4-mini

Evidence

Sponsor: Rep. Perez, Marie Gluesenkamp [D-WA-3]. Latest Action: House - 11/10/2023 Referred to the Subcommittee on Innovation, Data, and Commerce. This bill has the status Introduced. Official title: To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market.

Perez introduced a bill directly aimed at speeding generic and biosimilar market entry by banning pay-for-delay deals, but Congress.gov still lists the measure only as introduced with its last action a subcommittee referral. No enactment or House passage is shown, so the commitment remains unresolved as of the refresh window.

unresolved same_term A for effort

All Information for H.R.6275 - Protecting Consumer Access to Generic Drugs Act of 2023
secondary · model gpt-5.5 · confidence 96%

Rep. Marie Gluesenkamp Perez, along with Reps. Sean Casten and Gerry Connolly, introduced the Protecting Consumer Access to Generic Drugs Act of 2023. The release says the bill would end harmful pay-for-delay practices and provide FTC enforcement authority so people can access lower-priced generic drugs.

Her office announced concrete legislative action matching the promise: a bill to address patent-settlement delays that keep generic drugs out of the market. This is meaningful effort, but not proof of delivery because the bill had not become law.

partial same_term A for effort

Gluesenkamp Perez, Casten, Connolly Introduce Bill to Support Access to Lower-Priced Generic Drugs
secondary · model gpt-5.5 · confidence 94%

GovInfo lists H.R. 6275 as introduced in House, sponsored by Marie Gluesenkamp Perez, with the full title: To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry.

The authenticated bill text confirms Perez’s legislative proposal was specifically designed to speed generic and biosimilar entry by prohibiting compensation-for-delay arrangements. It supports partial progress, not completed delivery.

partial same_term A for effort

H.R. 6275 (IH) - Protecting Consumer Access to Generic Drugs Act of 2023
secondary · model gpt-5.5 · confidence 93%

Assessments

never unknown A for effort

Perez made a serious same-term legislative attempt by sponsoring H.R. 6275, the Protecting Consumer Access to Generic Drugs Act of 2023, to ban pay-for-delay deals that delay generic and biosimilar entry. But the measure did not advance beyond introduction/subcommittee referral in the 118th Congress, and there is no enacted, candidate-creditable federal outcome showing the promise was delivered. Introduction without passage or implementation is effort, not fulfillment.

provider codex_cli · model gpt-5.5 · confidence 94%